BR0201087A - Compostos antiinflamatórios de benzotriazol - Google Patents

Compostos antiinflamatórios de benzotriazol

Info

Publication number
BR0201087A
BR0201087A BR0201087-9A BR0201087A BR0201087A BR 0201087 A BR0201087 A BR 0201087A BR 0201087 A BR0201087 A BR 0201087A BR 0201087 A BR0201087 A BR 0201087A
Authority
BR
Brazil
Prior art keywords
alkyl
nitrogen
hydrogen
group
suitable substituents
Prior art date
Application number
BR0201087-9A
Other languages
English (en)
Inventor
Michael Anthony Letavic
Mark Anthony Dombroski
Kim Francis Mcclure
Ellen Ruth Laird
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0201087A publication Critical patent/BR0201087A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

"COMPOSTOS ANTIINFLAMATóRIOS DE BENZOTRIAZOL". A presente invenção está relacionado com novos benzotriazóis da fórmula I em que Het é um heterocíclico de 5 membros opcionalmente substituído contendo um ou dois átomos diferentes selecionados entre nitrogênio, enxofre e oxigênio, em que pelo menos um dos referidos átomos diferentes deve ser nitrogênio; R^ 2^ é selecionado do grupo constituído por hidrogênio, alquila (C~ 1~-C~ 6~) ou outros substituintes adequados; R^ 3^ é selecionado do grupo constituído por hidrogênio, alquila (C~ 1~-C~ 6~) Ou outros substituintes adequados; e s é um inteiro de 0-5; intermediários para a sua preparação, composições farmacêuticas incluindo-os e sua utilização em medicina. Os compostos da presente invenção são inibidores potentes das cinases MAP, de preferência da cinase p38. Eles são úteis no tratamento de inflamação, osteoartrite, artrite reumatóide, câncro, reperfusão ou isquemia em acidente vascular cerebral ou ataque cardíaco, doenças auto-imunes e outras distúrbios.
BR0201087-9A 2001-04-04 2002-04-04 Compostos antiinflamatórios de benzotriazol BR0201087A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28133101P 2001-04-04 2001-04-04

Publications (1)

Publication Number Publication Date
BR0201087A true BR0201087A (pt) 2003-05-27

Family

ID=23076827

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0201087-9A BR0201087A (pt) 2001-04-04 2002-04-04 Compostos antiinflamatórios de benzotriazol

Country Status (9)

Country Link
US (1) US6664395B2 (pt)
EP (1) EP1247810B1 (pt)
JP (1) JP3832646B2 (pt)
AT (1) ATE304009T1 (pt)
BR (1) BR0201087A (pt)
CA (1) CA2379903C (pt)
DE (1) DE60205974T2 (pt)
ES (1) ES2247271T3 (pt)
MX (1) MXPA02003454A (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
DE60227794D1 (de) * 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
WO2004041274A1 (en) * 2002-11-05 2004-05-21 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
WO2004099127A1 (en) * 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
MXPA05012377A (es) 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
CA2550064A1 (en) * 2003-12-18 2005-07-07 Pfizer Products Inc. Methods of treating acute inflammation in animals with p38 map kinase inhibitors
US7829560B2 (en) * 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
JP2008517064A (ja) * 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
AU2009232263B2 (en) * 2008-04-04 2013-07-04 Eli Lilly And Company 3-indazolyl-4-pyridylisothiazoles
US8410128B2 (en) 2008-06-20 2013-04-02 Bristol-Myers Squibb Company Triazolopyridine compounds useful as kinase inhibitors
KR20110100241A (ko) * 2008-12-05 2011-09-09 아르퀼 인코포레이티드 Ｒａｆ 억제제 및 이들의 용도
WO2010141360A1 (en) * 2009-06-05 2010-12-09 Merck Sharp & Dohme Corp. Biaryl benzotriazole derivatives
EP2931883B1 (en) * 2012-12-17 2017-02-01 Allinky Biopharma P38 mapk inhibitors for the treatment of inflammatory diseases
WO2014208296A1 (ja) * 2013-06-25 2014-12-31 イハラケミカル工業株式会社 ニトロベンゼン化合物を製造する方法
CN105481863B (zh) * 2015-12-09 2018-11-02 科贝源(北京)生物医药科技有限公司 2-甲基-6-(4-甲基苯磺酰基)-1,4,5,6-四氢咪唑并[4,5-d][1]苯并氮杂*的合成方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2018231745A1 (en) * 2017-06-14 2018-12-20 Trevena, Inc. Compounds for modulating s1p1 activity and methods of using the same
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US11884655B2 (en) 2019-11-19 2024-01-30 Trevena, Inc. Compounds and methods of preparing compounds S1P1 modulators
CN115490646A (zh) * 2022-10-10 2022-12-20 安徽昊帆生物有限公司 3-硝基-1，2，4-三氮唑的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283753A (en) * 1976-01-01 1977-07-12 Fuji Photo Film Co Ltd Benzotriazole
US5716972A (en) 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
DE69421624T2 (de) 1993-09-17 2000-07-20 Smithkline Beecham Corp Medikamente bindendes protein
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
NZ327044A (en) * 1996-01-11 2000-01-28 Smithkline Beecham Corp Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
JP2002516325A (ja) 1998-05-26 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規な置換イミダゾール化合物
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
PT1140916E (pt) 1998-12-16 2003-03-31 Aventis Pharma Ltd Acetais heteroarilo ciclicos
EP1140083A4 (en) 1999-01-08 2004-01-02 Smithkline Beecham Corp NEW CONNECTIONS
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

Also Published As

Publication number Publication date
US6664395B2 (en) 2003-12-16
DE60205974D1 (de) 2005-10-13
ES2247271T3 (es) 2006-03-01
EP1247810A1 (en) 2002-10-09
EP1247810B1 (en) 2005-09-07
DE60205974T2 (de) 2006-06-29
MXPA02003454A (es) 2004-07-16
ATE304009T1 (de) 2005-09-15
CA2379903A1 (en) 2002-10-04
JP3832646B2 (ja) 2006-10-11
JP2002308872A (ja) 2002-10-23
US20030078432A1 (en) 2003-04-24
CA2379903C (en) 2006-08-01

Similar Documents

Publication Publication Date Title
BR0201087A (pt) Compostos antiinflamatórios de benzotriazol
BR0207957A (pt) Compostos antiinflamatórios de benzimidazol
BR0207990A (pt) Compostos antinflamatórios de triazolopiridinas
JP4052573B2 (ja) イソオキサゾールおよびｅｒｋのインヒビターとしてのその使用
CA2381882C (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AU2001284192B2 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
CA2616451C (en) Substituted benzyl derivatives as gsk-3 inhibitors
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
DK0853083T3 (da) Pyridylfuran- og piridylthiophenforbindelser og farmaceutisk anvendelse deraf
WO2002092573A3 (en) Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
MA26868A1 (fr) Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases
HUP9902121A2 (hu) Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
TR200200778T2 (tr) Pirazol türevleri.
AP2004003028A0 (en) Benzamide and heteroarylamide as P2X7 receptor antagonists
ATE292118T1 (de) Pyrazolderivative als p-38 map kinase inhibitoren
CA2684169A1 (en) Smac mimetic dimers and trimers useful as anti-cancer agents
PT1161428E (pt) Compostos de pirimidina
BRPI0407999A (pt) compostos heteroaromáticos fundidos como inibidores do fator de transformação do crescimento (tgf)
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
BR0206698A (pt) Derivados de imidazolila como inibidores de fator de liberação de corticotropina.
HUP0301032A2 (hu) Ciklin-dependens kinázok N-{5-[(5-alkil-2-oxazolil)-metil-tio]-2-tiazolil}-karboxamid inhibitorai, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
Zhang et al. Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core
ATE246684T1 (de) Substituierte 1,4-dihydroindeno(1,2-c)pyrazole als inhibitoren von tyrosinkinase
KR910002437A (ko) 항염증성 조성물, 항알레르기성 조성물 또는 이들 혼합성질의 조성물

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.